Blue Trust Inc. Boosts Stake in Axon Enterprise, Inc. (NASDAQ:AXON)

Blue Trust Inc. lifted its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 987.5% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 87 shares of the biotechnology company’s stock after acquiring an additional 79 shares during the quarter. Blue Trust Inc.’s holdings in Axon Enterprise were worth $27,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. ING Groep NV boosted its holdings in shares of Axon Enterprise by 9.3% during the 4th quarter. ING Groep NV now owns 9,643 shares of the biotechnology company’s stock valued at $2,491,000 after acquiring an additional 821 shares during the last quarter. Avantax Advisory Services Inc. boosted its holdings in Axon Enterprise by 0.8% in the first quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock worth $1,659,000 after purchasing an additional 40 shares during the last quarter. GSA Capital Partners LLP bought a new stake in Axon Enterprise in the 1st quarter worth approximately $931,000. Sumitomo Mitsui Trust Holdings Inc. grew its position in Axon Enterprise by 14.8% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 170,376 shares of the biotechnology company’s stock worth $53,307,000 after purchasing an additional 22,013 shares during the period. Finally, Apollon Wealth Management LLC purchased a new stake in Axon Enterprise during the 4th quarter valued at $234,000. 79.08% of the stock is currently owned by institutional investors.

Insider Activity at Axon Enterprise

In related news, Director Julie A. Cullivan sold 478 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $286.04, for a total value of $136,727.12. Following the transaction, the director now directly owns 5,546 shares of the company’s stock, valued at approximately $1,586,377.84. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, Director Julie A. Cullivan sold 478 shares of the firm’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $286.04, for a total transaction of $136,727.12. Following the completion of the transaction, the director now directly owns 5,546 shares of the company’s stock, valued at $1,586,377.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Julie A. Cullivan sold 993 shares of the business’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $281.72, for a total transaction of $279,747.96. Following the completion of the sale, the director now owns 4,553 shares in the company, valued at approximately $1,282,671.16. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 3,921 shares of company stock valued at $1,313,659. 6.10% of the stock is owned by company insiders.

Analyst Ratings Changes

AXON has been the topic of a number of research reports. Barclays raised their price target on Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Craig Hallum raised their target price on Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $400.00 price target on shares of Axon Enterprise in a research report on Wednesday, August 7th. JMP Securities reissued a “market outperform” rating and issued a $375.00 price objective on shares of Axon Enterprise in a report on Wednesday, August 7th. Finally, Bank of America began coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $380.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $358.08.

Axon Enterprise Stock Down 0.5 %

Shares of AXON stock opened at $370.70 on Friday. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. Axon Enterprise, Inc. has a one year low of $189.12 and a one year high of $378.89. The company’s fifty day moving average price is $318.22 and its 200-day moving average price is $304.78. The company has a market capitalization of $28.01 billion, a price-to-earnings ratio of 108.39, a PEG ratio of 10.01 and a beta of 0.95.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The business had revenue of $504.00 million during the quarter, compared to analyst estimates of $478.35 million. During the same quarter in the prior year, the business posted $0.80 EPS. Axon Enterprise’s revenue for the quarter was up 34.5% compared to the same quarter last year. Sell-side analysts expect that Axon Enterprise, Inc. will post 1.79 EPS for the current fiscal year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.